Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,269,975 | 8,404,453 | 7,622,070 | 920,774 | 2,089,719 |
| Marketable Securities | 2,461,955 | 3,031,871 | 1,418,902 | 691,163 | 2,640,026 |
| Receivables | 12,675,030 | 11,737,310 | 10,985,560 | 10,446,800 | 10,927,900 |
| Inventories | 5,923,105 | 5,592,946 | 5,246,171 | 4,892,160 | 4,618,957 |
| Other current assets | -5 | 0 | 340,547 | 2 | -2 |
| TOTAL | $23,330,060 | $28,766,580 | $25,613,250 | $16,950,900 | $20,276,600 |
| Non-Current Assets | |||||
| PPE Net | 23,560,760 | 17,663,240 | 15,870,110 | 14,302,290 | 13,207,540 |
| Investments And Advances | 388,165 | 301,728 | 239,394 | 240,386 | 241,468 |
| Intangibles | 16,108,050 | 8,031,531 | 8,008,794 | 8,683,584 | 8,770,951 |
| Other Non-Current Assets | 4,153,235 | 3,819,721 | 3,570,422 | 3,345,740 | 3,166,811 |
| TOTAL | $44,210,210 | $29,816,220 | $27,688,720 | $26,572,000 | $25,386,770 |
| Total Assets | $67,540,270 | $58,582,800 | $53,301,970 | $43,522,900 | $45,663,370 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,901,385 | 813,648 | 786,724 | 1,479,878 | 940,606 |
| Accounts payable and accrued liabilities | 4,182,670 | 3,549,245 | 4,294,224 | 1,893,674 | 3,717,991 |
| Other current liabilities | 24,048,690 | 24,189,520 | 21,182,090 | 19,870,320 | 18,942,070 |
| TOTAL | $31,541,560 | $30,711,970 | $27,115,270 | $24,112,230 | $24,633,910 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,002,730 | 7,584,025 | 7,447,034 | 2,440,838 | 2,980,666 |
| Other Non-Current Liabilities | 1,403,750 | 1,246,118 | 1,198,700 | 1,161,306 | 1,100,616 |
| TOTAL | $15,193,250 | $10,105,890 | $9,949,773 | $5,009,222 | $5,556,804 |
| Total Liabilities | $46,734,800 | $40,817,860 | $37,065,040 | $29,121,460 | $30,190,710 |
| Shareholders' Equity | |||||
| Common Shares | 64,670 | 65,740 | 64,358 | 65,666 | 65,485 |
| Retained earnings | 20,944,960 | 17,934,160 | 16,183,250 | 14,421,680 | 15,222,620 |
| Other shareholders' equity | -204,160 | -234,960 | -10,688 | -84,906 | 185,555 |
| TOTAL | $20,805,470 | $17,764,940 | $16,236,920 | $14,401,440 | $15,472,660 |
| Total Liabilities And Equity | $67,540,270 | $58,582,800 | $53,301,960 | $43,522,900 | $45,663,370 |